Study Tests Arthritis Drug for Hard-to-Treat Depression
A small clinical trial examined whether tocilizumab, an anti-inflammatory drug used for rheumatoid arthritis, could reduce symptoms in patients who have not responded to standard antidepressants. The University of Bristol study involved 30 participants and found greater improvements among those who received the drug compared with placebo.
neurosciencenews.comResearchers at the University of Bristol tested an existing rheumatoid arthritis drug as a potential treatment for patients whose depression has not improved with conventional antidepressants. The trial enrolled 30 people with moderate-to-severe depression.
Half received tocilizumab, which blocks the inflammatory protein interleukin-6, while the other half received a placebo. Participants who received tocilizumab showed greater reductions in depressive symptoms, fatigue, and anxiety over time than those who received the placebo.
Standard antidepressant medications target brain chemicals including serotonin, norepinephrine, and dopamine. Roughly one in three people with depression do not respond to these treatments. Prior research has found that about one-third of people with depression show elevated inflammatory markers in their blood, including higher levels of interleukin-6.
Senior author Professor Golam Khandakar said the trial is one of the first randomized controlled studies to test immunotherapy for depression and the first to target the IL-6 receptor in selected patients. Lead author Dr Eimear Foley said the results move researchers closer to matching treatments to individual biology.
The researchers stated that a larger phase III trial will be required before doctors can consider prescribing the drug for depression.
Key Facts
Story Timeline
3 events- Recent
University of Bristol researchers completed a 30-person trial of tocilizumab for depression.
1 sourceThe Independent - Recent
Participants receiving tocilizumab showed greater symptom improvement than those on placebo.
1 sourceThe Independent - Future
A larger phase III trial is planned to confirm whether the drug can be prescribed for depression.
1 sourceThe Independent
Potential Impact
- 01
A larger trial could determine whether tocilizumab becomes an approved treatment option for some patients.
- 02
If effective, the approach may lead to new inflammation-targeted therapies for depression.
Transparency Panel
Related Stories
The GuardianWHO Chief Visits DRC as Ebola Death Rate Reaches 30-50%
World Health Organization director-general Tedros Adhanom Ghebreyesus arrived in the Democratic Republic of the Congo to support containment of a new Ebola outbreak. The agency revised the death rate to 30-50% based on confirmed cases and recorded 10 confirmed and 223 suspected d…
westernjournal.comGreek National Charged in UK With Aiding Iran-Linked Intelligence Service
A 46-year-old Greek man living in Germany was charged under the UK National Security Act with assisting an intelligence service believed to be Iran by targeting a journalist at Iran International.
straitstimes.comJournalists in Gaza to Receive 2026 Golden Pen of Freedom Award
Three international news agencies will accept the award on behalf of their local staff still reporting from the territory. The World Association of News Publishers cited the journalists' continued coverage under extreme conditions.